SAB4200621
Monoclonal Anti-NG2/CSPG4 antibody produced in mouse
clone 2164B6, purified from hybridoma cell culture
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(2)
About This Item
UNSPSC-Code:
12352203
NACRES:
NA.41
Empfohlene Produkte
Biologische Quelle
mouse
Qualitätsniveau
Konjugat
unconjugated
Antikörperform
purified immunoglobulin
Antikörper-Produkttyp
primary antibodies
Klon
2164B6, monoclonal
Form
buffered aqueous solution
Speziesreaktivität
human
Konzentration
~1 mg/mL
Methode(n)
flow cytometry: 2.5-5 μg/test using SK-Mel-28 cells.
immunofluorescence: 2.5-5 μg/mL using A375 cells.
Isotyp
IgG1
UniProt-Hinterlegungsnummer
Versandbedingung
dry ice
Lagertemp.
−20°C
Posttranslationale Modifikation Target
unmodified
Angaben zum Gen
human ... CSPG4(1464)
Allgemeine Beschreibung
Nerve/glial antigen 2 (NG2), a high molecular mass melanoma- associated antigen (HMW-MAA), is a large integral membrane, cell surface type I transmembrane protein that is covalently modified with chondroitin sulfate glycosaminoglycan.
Immunogen
a recombinant extracellular portion of human NG2 proteoglycan
Anwendung
Monoclonal Anti-NG2/CSPG4 antibody produced in mouse used in flow cytometry and immunocytochemistry.
Biochem./physiol. Wirkung
Nerve/glial antigen 2 (NG2) plays a central role in linking multiple oncogenic pathways required for malignant progression. NG2 expression in radial growth phase (RGP) human melanomas enables migration, protease activation and epithelial to mesenchymal transition, which is important in primary tumors for facilitating progression from a radial to vertical growth phase phenotype. It regulates sustained, high-level activation of key survival and growth pathways, integrin-regulated focal adhesion kinase (FAK), extracellular signal-regulated kinases 1 and 2 (ERK 1,2) and phosphoinositide 3-kinase (PI3K)/AKT pathways.
Physikalische Form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Haftungsausschluss
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Produkt-Auswahlhilfe.
Lagerklassenschlüssel
10 - Combustible liquids
WGK
WGK 1
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Megan S Lord et al.
The FEBS journal, 280(10), 2490-2510 (2013-02-20)
Proteoglycans are ubiquitous dynamic molecules that are made up of a protein core to which specific linear glycosylation structures, known as glycosaminoglycans, have been covalently coupled. They have roles in many biological and pathological processes, which have been shown to
X Wang et al.
Current molecular medicine, 10(4), 419-429 (2010-05-12)
Chondroitin sulfate proteoglycan 4 (CSPG4), also known as High Molecular Weight-Melanoma Associated Antigen, is a cell surface proteoglycan which has been recently shown to be expressed not only by melanoma cells, but also by various types of human carcinoma and
Matthew A Price et al.
Pigment cell & melanoma research, 24(6), 1148-1157 (2011-10-19)
Chondroitin sulfate proteoglycan 4 (CSPG4), a transmembrane proteoglycan originally identified as a highly immunogenic tumor antigen on the surface of melanoma cells, is associated with melanoma tumor formation and poor prognosis in certain melanomas and several other tumor types. The
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Xinhui Wang et al.
Journal of the National Cancer Institute, 102(19), 1496-1512 (2010-09-21)
The cell surface proteoglycan, chondroitin sulfate proteoglycan 4 (CSPG4), is a potential target for monoclonal antibody (mAb)-based immunotherapy for many types of cancer. The lack of effective therapy for triple-negative breast cancer (TNBC) prompted us to examine whether CSPG4 is
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.